Cardiothoracic & Transplant SurgeryDr. Biswarup PurkayasthaHeart Failure & Coronary Artery Disease

Consultant - Heart & Lung Transplant and Vascular Surgery, Artemis Hospitals, Gurgaon

Series overview · 14 articles

Heart Failure and Coronary Artery Disease in the African Population

June 28, 2026

Dr. Biswarup Purkayastha is Consultant in Heart & Lung Transplant and Vascular Surgery at Artemis Hospitals, Gurgaon. This guide is based on a live Jivo Masterclass where he laid out, for doctors across Africa, why heart failure and coronary artery disease behave so differently on the continent than almost anywhere else in the world: arriving a decade earlier, diagnosed later, and treated on medications that are often outdated by the time a patient reaches a specialist.

The series covers what's actually driving heart failure across Africa (hypertension, rheumatic disease, HIV, tuberculosis), how a six-specialty heart team decides between medical therapy, valve surgery, LVAD support and transplant, the modern drug classes that have moved treatment beyond digoxin, and the evidence comparing PCI against CABG for coronary artery disease, a disease killing roughly twice as many people in sub-Saharan Africa each year as cancer.

It closes with Dr. Purkayastha's own answers to the doctors who joined: on valve repair versus replacement, the alcohol-and-cardiomyopathy myth, why fit athletes still have cardiac events, and where LVAD technology and xenotransplantation are heading over the next decade.

This guide is based on a live Jivo Masterclass — Dr. Biswarup Purkayastha taught doctors across Africa on June 28, 2026.

Watch the full recording, or read the guide above.

FROM THE LIVE Q&A

HO

Host (Varun, Jivo Healthcare)

Regarding valve repair strategies in heart failure, specifically a tricuspid valve case where the options are mechanical valve, bioprosthetic valve, or transcatheter edge-to-edge repair (TEER) — which is preferred and when?

BP

Dr. Biswarup Purkayastha

The tricuspid valve is more often repaired than replaced. Even in a moderately aged patient in the 50 to 60 age group, if tricuspid valve replacement is necessary, a bioprosthetic valve is preferable to a mechanical valve — the right side is a low-pressure circuit, so a mechanical valve there carries a very high thrombosis risk that can embolise to the lung and be fatal. The preferred approach overall is tricuspid repair, either a traditional DeVega repair or an annuloplasty ring. TEER (TriClip for the tricuspid, MitraClip for the mitral) warrants real caution — for the mitral valve it's the surgical community's last resort, used only when every other repair technique and replacement are precluded by financial or anatomical constraint. With today's preoperative 3D imaging of the mitral annulus, a surgeon can nearly always plan intervention in advance instead.

See all 9 questions from this masterclass →

Book a Consultation with Dr. Biswarup Purkayastha

Book on WhatsApp

Or message us on WhatsApp: +91 98182 98669

Frequently Asked Questions

What is the role of traditional alcohol in cardiomyopathy?

The evidence is unambiguous: any form of alcohol predisposes to cardiac dysfunction. Traditional drinks have been examined alongside commercially available alcohol in studies, and the myth that red wine protects the heart has been comprehensively debunked. Chronic alcohol consumption damages the heart, full stop. Whether someone chooses to drink socially is a personal decision, but scientifically there is no basis for recommending any alcohol for cardiac health.

How do you manage the bleeding risk when loading a patient with 600mg aspirin and clopidogrel?

You do not manage it — you accept it, because that is your best option to open the coronary artery blockage. The bleeding risk is only a problem in a living patient. If the patient dies from a myocardial infarction for lack of intervention, there is no bleeding to manage.

What is the primary indication for using sacubitril/valsartan, and how is it dosed?

It should be started at the lowest possible dose — half a tablet, 25mg once daily, titrated over a week to 50mg, then 100mg, not typically exceeding 100mg once daily or 50mg twice daily. The primary indication is ejection fraction below 45% with elevated NT-proBNP. In a patient with ejection fraction below 35% and high NT-proBNP, it should be initiated at the lowest dose and titrated carefully upward.

From your experience, what is the relative epidemiology of coronary artery disease in Africans, Asians, and Caucasians? Are there differences in surgical outcomes across these populations?

In Africans and Asians, coronary artery disease is largely driven by genetic predisposition. In Caucasians, the predominant driver is sedentary lifestyle combined with diet — high-fat foods, alcohol, physical inactivity — which more than compensates for their lesser genetic predisposition. Surgical outcomes are comparable worldwide, with success rates upward of 90% and combined morbidity and mortality after CABG around 5 to 7% regardless of country. But the numbers in Asia and Africa are hugely underrepresented — if one million cardiac deaths annually in sub-Saharan Africa is the current reported figure, the true number with adequate diagnostic infrastructure would likely be closer to three million.

Regarding the 2-3-4-5 plant-based diet pyramid — India has a large vegetarian population that nominally follows this diet, yet cardiac events have increased significantly over the last two to three decades. How do you explain that?

The traditional Indian vegetarian population was genuinely following something close to this diet. What changed was cooking oil. Industrial cooking oils were repackaged and marketed under omega fatty acid branding — omega-3, then omega-6, now omega-9 — persuading consumers to abandon traditional cooking fats like mustard oil and olive oil for artificially processed, packaged products whose health claims aren't supported by meaningful clinical evidence. If the population simply returned to traditional cooking oils, it would likely cut the cardiac disease burden significantly. The pyramid isn't the problem; the oil in the pan is.

Who is Dr. Biswarup Purkayastha and what is his specialty?

He is Consultant in Heart & Lung Transplant and Vascular Surgery at Artemis Hospitals, Gurgaon. His Jivo Masterclass explains why heart failure and coronary artery disease behave differently across Africa than almost anywhere else in the world.

What makes heart failure in Africa different from heart failure elsewhere?

It arrives roughly a decade earlier, is diagnosed later, and is frequently treated on medications that are already outdated by the time a patient reaches a specialist.

What are the main drivers of heart failure covered in this masterclass series?

Hypertension, rheumatic disease, HIV and tuberculosis, the conditions driving the bulk of heart failure across the continent.

How does coronary artery disease compare to cancer as a cause of death in sub-Saharan Africa?

It kills roughly twice as many people in sub-Saharan Africa each year as cancer does.

Need Expert Medical Guidance?

Connect with leading specialists through the Jivo Healthcare network for personalized advice.

Get Expert Opinion